en
svPress releases
Regulatory press release 2021-01-22
Xspray Pharmas study with modified formulation of HyNap-Dasa has now started
Regulatory press release 2021-01-14
Xspray Pharma announces results from additional bioequivalence study and provides update regarding upcoming regulatory applications for ANDA and 505(b)(2)
Press release 2020-12-30
Xspray Pharma reports positive results from a study with dasatinib during omeprazole treatment
Regulatory press release 2020-12-29
Xspray Pharma’s HyNap-Nilo receives FDA Orphan Drug Designation for the treatment of Chronic Myeloid Leukemia
Press release 2020-12-17
Xspray Pharma moves up to Nasdaq Stockholm’s Mid Cap-segment
Regulatory press release 2020-12-11
Xspray Pharma has decided to await the result of two ongoing clinical studies before submitting its ANDA application
Regulatory press release 2020-11-20
Xspray Pharma publishes Interim Report Q3, January – September 2020
Regulatory press release 2020-10-30
Number of shares and votes in Xspray
Press release 2020-10-21
Xspray Pharma’s Nomination Committee for the Annual General Meeting 2021
Regulatory press release 2020-10-20